Vertex to acquire Concert Pharmaceuticals ’ cystic fibrosis drug for $250m

US-based Vertex Pharmaceuticals has signed an agreement to acquire CTP-656, an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator from Concert Pharmaceuticals for up to $250m.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news